Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Katsumi Iga"'
Autor:
Katsumi Iga, Akiko Kiriyama
Purpose It is challenging to predict CYP2C8-mediated drug-drug interactions (DDIs) produced by clopidogrel (Clop) and gemfibrozil (Gem) by maintaining the victim’s fractional CYP2C8-mediated clearance (fm,CYP2C8) constant. The goal is to develop a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::217b9837b9a911b0efe0cb2cf59d8204
https://doi.org/10.21203/rs.3.rs-2364592/v1
https://doi.org/10.21203/rs.3.rs-2364592/v1
Autor:
Shiori Sakata, Shunsuke Kimura, Katsumi Iga, Reiko Yutani, Daisuke Inoue, Akiko Tanaka, Akiko Kiriyama, Akira Yamamoto, Hidemasa Katsumi, Erika Nishimura, Tomoyuki Furubayashi, Toshiyasu Sakane, Kosuke Kusamori
Publikováno v:
Biological and Pharmaceutical Bulletin. 41:1769-1777
We reported a novel transport mechanism of curcumin, independent of improved solubility, which involved direct contact of amorphous solid particles with the cell membrane. This mechanism has potential as a novel systemic delivery system of poorly wat
Autor:
Katsumi Iga, Akiko Kiriyama
Publikováno v:
Journal of Pharmaceutical Sciences. 106:1426-1438
In order to predict cytochrome P450 3A4 (CYP3A4)-mediated drug-drug interactions (DDIs), a simple 2-compartment model-assisted, overall inhibition activity (Ai,overall) method was derived based on 2 concepts. One concept was that the increase in bloo
Autor:
Katsumi Iga, Akiko Kiriyama
Publikováno v:
Biological & Pharmaceutical Bulletin. 40:2024-2037
Our study of drug-drug interaction (DDI) started with the clarification of unusually large DDI observed between ramelteon (RAM) and fluvoxamine (FLV). The main cause of this DDI was shown to be the extremely small hepatic availability of RAM (vFh). T
Autor:
Katsumi Iga
Publikováno v:
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 139(3)
In this review, 9 compounds with insufficient absorption characteristics, safety or efficacy were selected from among the compounds for which the author was in charge of development between 2000 and 2005, in order to evaluate the pharmacokinetic (PK)
Autor:
Katsumi Iga
Publikováno v:
Journal of Pharmaceutical Sciences. 105:1307-1317
Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model
Autor:
Masakazu Enomura, Daisuke Inoue, Akiko Kiriyama, Kosuke Kusamori, Akira Yamamoto, Toshiyasu Sakane, Mai Yoshizumi, Akiko Tanaka, Reiko Yutani, Katsumi Iga, Shunsuke Kimura, Kaeko Araki, Hidemasa Katsumi, Reiko Teraoka, Tomoyuki Furubayashi
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 122
Amorphization has been widely recognized as a useful solubilization technique for poorly water-soluble drugs, such as curcumin. We have recently reported the novel finding that the membrane transport of curcumin was markedly enhanced when amorphous s
Autor:
Chizuki Banba, Rie Yajima, Miki Yamakawa, Akiko Kiriyama, Shunsuke Kimura, Akino Honbo, Katsumi Iga
Publikováno v:
Journal of Drug Metabolism & Toxicology.
Efficacy and safety of a drug and its plasma concentration are closely correlated, and plasma concentrations are used as an index of the drug’s effects. Therefore, it is important to understand the relationship between the drug’s plasma concentra
Publikováno v:
Therapeutic Delivery. 4:1261-1278
Over the past 20–30 years there has been quite a number of studies interested in polymeric nanoparticle (PNP) systems as a pharmaceutical approach for poorly soluble drugs, peptide drugs, gene and antibodies. Now, the products based on the PNP tech
Publikováno v:
Biomedicine & Aging Pathology. 3:107-114
Sensitivity of physiological and biochemical parameters based on aging, pathological conditions and drug combinations on propranolol pharmacokinetics was investigated to define factors contributing to larger inter-individual variability on propranolo